ALKS 5461 receives refusal-to-file for depression: industry news round-up

Written by Sharon Salt

In this week’s round-up, we cover the latest industry news from depression and Parkinson’s disease. Find out more below about our selection of the highlights this week. Our pick of the headlines include: ALKS 5461 receives refusual-to-file for depression Positive results reported for third study of cariprazine in bipolar I depression Fast Track Designation granted for apomorphine in Parkinson’s disease ALKS 5461 receives refusual-to-file letter for depression Earlier this week, Alkermes PLC (Dublin, Ireland) announced that it received a refusal-to-file letter from the US FDA regarding its new drug application for ALKS 5461, a once-daily, oral investigational drug for the...

To view the full article, please register now for access

It's completely free